IL-class biologics rebalancing immunology
IL-23 and IL-17 agents continue to take share from TNF inhibitors across rheumatology, IBD, and dermatology.
After a decade of TNF dominance, IL-class biologics are reshaping how rheumatologists, gastroenterologists, and dermatologists sequence therapy. Cross-indication competition is now the more interesting story.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?
- ExplainedWhat is Sjogren disease?
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.